Improving frequency of urinary albumin testing in type 2 diabetes in primary care — An analysis of cross-sectional studies in Denmark
•Albuminuria and kidney function are important renal risk factors.•Urine sample collection is a challenge to ensure quality of care.•Trials with SGLT2 inhibition underscores importance of albuminuria measurement.•We assessed cross-sectional studies of the last decade in Danish primary care.•We found...
Uloženo v:
| Vydáno v: | Primary care diabetes Ročník 15; číslo 6; s. 1007 - 1011 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Elsevier Ltd
01.12.2021
|
| Témata: | |
| ISSN: | 1751-9918, 1878-0210, 1878-0210 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | •Albuminuria and kidney function are important renal risk factors.•Urine sample collection is a challenge to ensure quality of care.•Trials with SGLT2 inhibition underscores importance of albuminuria measurement.•We assessed cross-sectional studies of the last decade in Danish primary care.•We found an improving frequency of renal risk assessment.
To ensure high quality standards in chronic care of type 2 diabetes, it is paramount to ensure regular measurement of clinical risk factors. For prevention of diabetic kidney disease, testing for albuminuria and kidney function is vital. The majority of individuals with type 2 diabetes in Denmark are treated in general practice, and given the recent development of kidney-protective treatments, a renewed focus on renal risk factors is important.
To assess the frequency of albuminuria and kidney function testing in general practice in Denmark and describe developments over the last decade. The proportion of patients with the recommended annual measurements of albuminuria and kidney function was the primary variable.
We used data from subjects with type 2 diabetes in three cross-sectional general practice studies from 2009 to 2017.
Data from 5592 individuals were available. Almost all subjects (96–99%) in the studies had annual measurement of kidney function performed. During the combined observation period there was a clear increase in the proportion of subjects that had albuminuria measured, from 57.2% to 68.0% to 82.8%.
The regular assessment of renal risk factors in individuals with type 2 diabetes attending primary care in Denmark has seemingly improved over the last decade. This provides the required base for renal risk assessment and appropriate therapy selection. |
|---|---|
| AbstractList | •Albuminuria and kidney function are important renal risk factors.•Urine sample collection is a challenge to ensure quality of care.•Trials with SGLT2 inhibition underscores importance of albuminuria measurement.•We assessed cross-sectional studies of the last decade in Danish primary care.•We found an improving frequency of renal risk assessment.
To ensure high quality standards in chronic care of type 2 diabetes, it is paramount to ensure regular measurement of clinical risk factors. For prevention of diabetic kidney disease, testing for albuminuria and kidney function is vital. The majority of individuals with type 2 diabetes in Denmark are treated in general practice, and given the recent development of kidney-protective treatments, a renewed focus on renal risk factors is important.
To assess the frequency of albuminuria and kidney function testing in general practice in Denmark and describe developments over the last decade. The proportion of patients with the recommended annual measurements of albuminuria and kidney function was the primary variable.
We used data from subjects with type 2 diabetes in three cross-sectional general practice studies from 2009 to 2017.
Data from 5592 individuals were available. Almost all subjects (96–99%) in the studies had annual measurement of kidney function performed. During the combined observation period there was a clear increase in the proportion of subjects that had albuminuria measured, from 57.2% to 68.0% to 82.8%.
The regular assessment of renal risk factors in individuals with type 2 diabetes attending primary care in Denmark has seemingly improved over the last decade. This provides the required base for renal risk assessment and appropriate therapy selection. To ensure high quality standards in chronic care of type 2 diabetes, it is paramount to ensure regular measurement of clinical risk factors. For prevention of diabetic kidney disease, testing for albuminuria and kidney function is vital. The majority of individuals with type 2 diabetes in Denmark are treated in general practice, and given the recent development of kidney-protective treatments, a renewed focus on renal risk factors is important.BACKGROUNDTo ensure high quality standards in chronic care of type 2 diabetes, it is paramount to ensure regular measurement of clinical risk factors. For prevention of diabetic kidney disease, testing for albuminuria and kidney function is vital. The majority of individuals with type 2 diabetes in Denmark are treated in general practice, and given the recent development of kidney-protective treatments, a renewed focus on renal risk factors is important.To assess the frequency of albuminuria and kidney function testing in general practice in Denmark and describe developments over the last decade. The proportion of patients with the recommended annual measurements of albuminuria and kidney function was the primary variable.OBJECTIVETo assess the frequency of albuminuria and kidney function testing in general practice in Denmark and describe developments over the last decade. The proportion of patients with the recommended annual measurements of albuminuria and kidney function was the primary variable.We used data from subjects with type 2 diabetes in three cross-sectional general practice studies from 2009 to 2017.METHODSWe used data from subjects with type 2 diabetes in three cross-sectional general practice studies from 2009 to 2017.Data from 5592 individuals were available. Almost all subjects (96-99%) in the studies had annual measurement of kidney function performed. During the combined observation period there was a clear increase in the proportion of subjects that had albuminuria measured, from 57.2% to 68.0% to 82.8%.RESULTSData from 5592 individuals were available. Almost all subjects (96-99%) in the studies had annual measurement of kidney function performed. During the combined observation period there was a clear increase in the proportion of subjects that had albuminuria measured, from 57.2% to 68.0% to 82.8%.The regular assessment of renal risk factors in individuals with type 2 diabetes attending primary care in Denmark has seemingly improved over the last decade. This provides the required base for renal risk assessment and appropriate therapy selection.CONCLUSIONThe regular assessment of renal risk factors in individuals with type 2 diabetes attending primary care in Denmark has seemingly improved over the last decade. This provides the required base for renal risk assessment and appropriate therapy selection. To ensure high quality standards in chronic care of type 2 diabetes, it is paramount to ensure regular measurement of clinical risk factors. For prevention of diabetic kidney disease, testing for albuminuria and kidney function is vital. The majority of individuals with type 2 diabetes in Denmark are treated in general practice, and given the recent development of kidney-protective treatments, a renewed focus on renal risk factors is important. To assess the frequency of albuminuria and kidney function testing in general practice in Denmark and describe developments over the last decade. The proportion of patients with the recommended annual measurements of albuminuria and kidney function was the primary variable. We used data from subjects with type 2 diabetes in three cross-sectional general practice studies from 2009 to 2017. Data from 5592 individuals were available. Almost all subjects (96-99%) in the studies had annual measurement of kidney function performed. During the combined observation period there was a clear increase in the proportion of subjects that had albuminuria measured, from 57.2% to 68.0% to 82.8%. The regular assessment of renal risk factors in individuals with type 2 diabetes attending primary care in Denmark has seemingly improved over the last decade. This provides the required base for renal risk assessment and appropriate therapy selection. |
| Author | Charles, Morten Persson, Frederik Knudsen, Søren Tang Povlsen, Johan Vestergaard |
| Author_xml | – sequence: 1 givenname: Frederik orcidid: 0000-0001-6242-6638 surname: Persson fullname: Persson, Frederik email: frederik.persson@regionh.dk organization: Steno Diabetes Center Copenhagen, Gentofte, Denmark – sequence: 2 givenname: Morten surname: Charles fullname: Charles, Morten organization: Research Unit of General Practice, Aarhus University, Denmark – sequence: 3 givenname: Johan Vestergaard surname: Povlsen fullname: Povlsen, Johan Vestergaard organization: Dept. Renal Medicine C, Aarhus University Hospital, Aarhus, Denmark – sequence: 4 givenname: Søren Tang orcidid: 0000-0002-7020-6157 surname: Knudsen fullname: Knudsen, Søren Tang organization: Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34284949$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkb9u3SAYxVGVqklu-wBdKsYudgFjA-oUpf8iReqSzAjw54obG9-CHclbtr5AnzBPEtx7myFDMvHp6PyQzjmn6CiMARB6T0lJCW0-bcuda0tGGC2JKAmpXqETKoUsskKO8i1qWihF5TE6TWlLSEMrKd6g44ozyRVXJ-jPxbCL460Pv3AX4fcMwS147PAcfTBxwaa38-ADniBNq2k9lx1ghltvLGR5lXbRD6vbmQj4_u4vPgvYBNMvyaf1NxfHlIoEbvJjlnGa5tbv0S8QMnrzFr3uTJ_g3eHdoOtvX6_OfxSXP79fnJ9dFo7zZipaqxrGpWkbntOIjjJnhRG0MVLVzljXgeXKOLB1V4MgpqLMVoQ3VHHJDKk26OP-35w6p02THnxy0PcmwDgnzeq6koxUuakN-nCwznaAVh9C6v_lZQPdG_7Fi9A9WijR60B6q_NAeh1IE6HzQJkRTxjnJ7PWMkXj-2fJz3sScj23HqJOzue5oPUxF6vb0T9Lqye0633wzvQ3sLzAPgCIDr_W |
| CitedBy_id | crossref_primary_10_1016_j_focus_2023_100133 crossref_primary_10_1016_j_pcd_2025_05_002 crossref_primary_10_1155_2023_9609266 crossref_primary_10_1186_s12875_023_02077_7 crossref_primary_10_1016_j_eclinm_2025_103185 crossref_primary_10_1186_s12875_025_02721_4 crossref_primary_10_1016_j_amjmed_2021_11_019 crossref_primary_10_3390_jcm14103600 crossref_primary_10_7759_cureus_68584 |
| Cites_doi | 10.1038/ki.2012.18 10.1007/s00125-016-4065-6 10.1038/sj.ki.5001516 10.1371/journal.pone.0221325 10.1016/j.kint.2016.11.023 10.1016/S2213-8587(18)30314-0 10.1097/XCE.0000000000000135 10.1016/j.kisu.2017.10.003 10.1056/NEJMoa1515920 10.1056/NEJMoa0706245 10.1161/CIRCULATIONAHA.120.051824 10.1016/j.pcd.2020.09.006 10.1056/NEJMoa2024816 10.1056/NEJMoa1811744 10.1016/j.amjmed.2019.10.042 10.1371/journal.pone.0229621 10.2337/dci19-0066 10.1111/dom.12600 10.1161/CIRCULATIONAHA.120.050391 10.1038/sj.ki.5000377 10.1056/NEJMoa1616011 10.1136/bmjdrc-2017-000459 10.1016/S2213-8587(20)30369-7 10.1016/j.diabres.2014.10.014 10.1681/ASN.2012070718 10.1080/14728222.2019.1624721 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| Copyright_xml | – notice: 2021 The Authors – notice: Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.pcd.2021.07.003 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1878-0210 |
| EndPage | 1011 |
| ExternalDocumentID | 34284949 10_1016_j_pcd_2021_07_003 S1751991821001200 |
| Genre | Journal Article |
| GeographicLocations | Denmark |
| GeographicLocations_xml | – name: Denmark |
| GroupedDBID | --- --K --M -RU .1- .FO .~1 0R~ 123 1B1 1P~ 1~. 1~5 4.4 457 4G. 53G 5VS 7-5 71M 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABIVO ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACJTP ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXBA AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OB0 ON- OZT P-8 P-9 P2P PC. Q38 ROL RPZ SDF SDG SEL SES SNG SPCBC SSH SSZ T5K Z5R ~G- ~HD 6I. AACTN AAFTH AAIAV ABLVK ABYKQ AFCTW AFKWA AISVY AJBFU AJOXV AMFUW LCYCR NAHTW RIG 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c446t-db96248ad640067f12cb7a716a895cabcfeb49aceb5f5e70a312b304619482a03 |
| ISICitedReferencesCount | 9 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000744235900013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1751-9918 1878-0210 |
| IngestDate | Sun Sep 28 16:23:20 EDT 2025 Wed Feb 19 02:27:27 EST 2025 Sat Nov 29 06:58:05 EST 2025 Tue Nov 18 22:11:32 EST 2025 Fri Feb 23 02:41:51 EST 2024 Tue Oct 14 19:35:36 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Type 2 diabetes Albuminuria Primary care Diabetic kidney disease |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c446t-db96248ad640067f12cb7a716a895cabcfeb49aceb5f5e70a312b304619482a03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-6242-6638 0000-0002-7020-6157 |
| OpenAccessLink | https://dx.doi.org/10.1016/j.pcd.2021.07.003 |
| PMID | 34284949 |
| PQID | 2553820361 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_2553820361 pubmed_primary_34284949 crossref_primary_10_1016_j_pcd_2021_07_003 crossref_citationtrail_10_1016_j_pcd_2021_07_003 elsevier_sciencedirect_doi_10_1016_j_pcd_2021_07_003 elsevier_clinicalkey_doi_10_1016_j_pcd_2021_07_003 |
| PublicationCentury | 2000 |
| PublicationDate | December 2021 2021-12-00 20211201 |
| PublicationDateYYYYMMDD | 2021-12-01 |
| PublicationDate_xml | – month: 12 year: 2021 text: December 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Primary care diabetes |
| PublicationTitleAlternate | Prim Care Diabetes |
| PublicationYear | 2021 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Jhund, Solomon, Docherty, Heerspink, Anand, Böhm, Chopra, de Boer, Desai, Ge, Kitakaze, Merkely, O’Meara, Schou, Tereshchenko, Verma, Vinh, Inzucchi, Køber, Kosiborod, Martinez, Ponikowski, Sabatine, Bengtsson, Langkilde, Sjöstrand, McMurray (bib0130) 2021; 143 Gaede, Oellgaard, Carstensen, Rossing, Lund-Andersen, Parving, Pedersen (bib0010) 2016; 59 Warren, Knudsen, Cooper (bib0095) 2019; 23 Persson, Rossing (bib0030) 2018; 8 Sørensen, Hansen, Heaf, Feldt-Rasmussen (bib0125) 2006; 70 Wheeler, Stefánsson, Jongs, Chertow, Greene, Hou, McMurray, Correa-Rotter, Rossing, Toto, Sjöström, Langkilde, Heerspink (bib0140) 2021; 9 Perkovic, Jardine, Neal, Bompoint, Heerspink, Charytan, Edwards, Agarwal, Bakris, Bull, Cannon, Capuano, Chu, de Zeeuw, Greene, Levin, Pollock, Wheeler, Yavin, Zhang, Zinman, Meininger, Brenner, Mahaffey, C.T. Investigators (bib0080) 2019; 380 Sperati, Soman, Agrawal, Liu, Abdel-Kader, Diamantidis, Estrella, Cavanaugh, Plantinga, Schell, Simon, Vassalotti, Choi, Jaar, Greer (bib0110) 2019; 14 Parving, Persson, Rossing (bib0025) 2015; 107 Knudsen, Mosbech, Hansen, Konig, Johnsen, Kamper (bib0055) 2012; 59 Parving, Lewis, Ravid, Remuzzi, Hunsicker (bib0050) 2006; 69 Gaede, Lund-Andersen, Parving, Pedersen (bib0005) 2008; 358 Lambers Heerspink, Ninomiya, Persson, Brenner, Brunel, Chaturvedi, Desai, Haffner, McMurray, Solomon, Pfeffer, Parving, de Zeeuw (bib0040) 2016; 18 Jain, Cuerden, McLeod, Hemmelgarn, Akbari, Tonelli, Quinn, Oliver, Garg (bib0115) 2012; 81 Mann, Orsted, Brown-Frandsen, Marso, Poulter, Rasmussen, Tornoe, Zinman, Buse, L.S. Committee, Investigators (bib0090) 2017; 377 Fangel, Nielsen, Kristensen, Larsen, Overvad, Lip, Jensen (bib0070) 2020; 133 Buse, Wexler, Tsapas, Rossing, Mingrone, Mathieu, D’Alessio, Davies (bib0020) 2020; 43 Rungby, Schou, Warrer, Ytte, Andersen (bib0060) 2017; 6 Lange, Petersen, Gerdes, Tarnow (bib0065) 2020; 67 Oellgaard, Gaede, Rossing, Persson, Parving, Pedersen (bib0015) 2017; 91 Anker, Butler, Filippatos, Khan, Marx, Lam, Schnaidt, Ofstad, Brueckmann, Jamal, Bocchi, Ponikowski, Perrone, Januzzi, Verma, Böhm, Ferreira, Pocock, Zannad, Packer (bib0135) 2021; 143 Bakke, Cooper, Thue, Skeie, Carlsen, Dalen, Lovaas, Madsen, Oord, Berg, Claudi, Tran, Gjelsvik, Jenum, Sandberg (bib0100) 2017; 5 Wanner, Inzucchi, Lachin, Fitchett, von Eynatten, Mattheus, Johansen, Woerle, Broedl, Zinman (bib0075) 2016; 375 Afkarian, Sachs, Kestenbaum, Hirsch, Tuttle, Himmelfarb, de Boer (bib0045) 2013; 24 Knudsen, Baggesen, Lajer, Nurkanovic, Ustyugova, Sørensen, Thomsen (bib0105) 2020; 15 Heerspink, Stefansson, Correa-Rotter, Chertow, Greene, Hou, Mann, McMurray, Lindberg, Rossing, Sjostrom, Toto, Langkilde, Wheeler, D.-C.T. Committees, Investigators (bib0085) 2020; 383 Heerspink, Greene, Tighiouart, Gansevoort, Coresh, Simon, Chan, Hou, Lewis, Locatelli, Praga, Schena, Levey, Inker, C. Chronic Kidney Disease Epidemiology (bib0035) 2019; 7 Knudsen, Bodegård, Birkeland, Furuseth, Thuresson, Lindh, Nilsson, Alvarsson, Jørgensen, Søndergaard, Persson (bib0120) 2021; 15 Heerspink (10.1016/j.pcd.2021.07.003_bib0085) 2020; 383 Knudsen (10.1016/j.pcd.2021.07.003_bib0105) 2020; 15 Sperati (10.1016/j.pcd.2021.07.003_bib0110) 2019; 14 Knudsen (10.1016/j.pcd.2021.07.003_bib0120) 2021; 15 Wanner (10.1016/j.pcd.2021.07.003_bib0075) 2016; 375 Lambers Heerspink (10.1016/j.pcd.2021.07.003_bib0040) 2016; 18 Rungby (10.1016/j.pcd.2021.07.003_bib0060) 2017; 6 Lange (10.1016/j.pcd.2021.07.003_bib0065) 2020; 67 Perkovic (10.1016/j.pcd.2021.07.003_bib0080) 2019; 380 Warren (10.1016/j.pcd.2021.07.003_bib0095) 2019; 23 Sørensen (10.1016/j.pcd.2021.07.003_bib0125) 2006; 70 Jain (10.1016/j.pcd.2021.07.003_bib0115) 2012; 81 Mann (10.1016/j.pcd.2021.07.003_bib0090) 2017; 377 Afkarian (10.1016/j.pcd.2021.07.003_bib0045) 2013; 24 Knudsen (10.1016/j.pcd.2021.07.003_bib0055) 2012; 59 Oellgaard (10.1016/j.pcd.2021.07.003_bib0015) 2017; 91 Parving (10.1016/j.pcd.2021.07.003_bib0025) 2015; 107 Fangel (10.1016/j.pcd.2021.07.003_bib0070) 2020; 133 Wheeler (10.1016/j.pcd.2021.07.003_bib0140) 2021; 9 Gaede (10.1016/j.pcd.2021.07.003_bib0010) 2016; 59 Parving (10.1016/j.pcd.2021.07.003_bib0050) 2006; 69 Bakke (10.1016/j.pcd.2021.07.003_bib0100) 2017; 5 Anker (10.1016/j.pcd.2021.07.003_bib0135) 2021; 143 Heerspink (10.1016/j.pcd.2021.07.003_bib0035) 2019; 7 Persson (10.1016/j.pcd.2021.07.003_bib0030) 2018; 8 Gaede (10.1016/j.pcd.2021.07.003_bib0005) 2008; 358 Jhund (10.1016/j.pcd.2021.07.003_bib0130) 2021; 143 Buse (10.1016/j.pcd.2021.07.003_bib0020) 2020; 43 |
| References_xml | – volume: 375 start-page: 323 year: 2016 end-page: 334 ident: bib0075 article-title: Empagliflozin and progression of kidney disease in type 2 diabetes publication-title: N. Engl. J. Med. – volume: 383 start-page: 1436 year: 2020 end-page: 1446 ident: bib0085 article-title: Dapagliflozin in patients with chronic kidney disease publication-title: N. Engl. J. Med. – volume: 23 start-page: 579 year: 2019 end-page: 591 ident: bib0095 article-title: Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies publication-title: Expert Opin. Ther. Targets – volume: 24 start-page: 302 year: 2013 end-page: 308 ident: bib0045 article-title: Kidney disease and increased mortality risk in type 2 diabetes publication-title: J. Am. Soc. Nephrol. – volume: 9 start-page: 22 year: 2021 end-page: 31 ident: bib0140 article-title: Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial publication-title: Lancet Diabetes Endocrinol. – volume: 91 start-page: 982 year: 2017 end-page: 988 ident: bib0015 article-title: Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits publication-title: Kidney Int. – volume: 377 start-page: 839 year: 2017 end-page: 848 ident: bib0090 article-title: Liraglutide and renal outcomes in type 2 diabetes publication-title: N. Engl. J. Med. – volume: 15 start-page: 262 year: 2021 end-page: 268 ident: bib0120 article-title: Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015 publication-title: Prim. Care Diabetes – volume: 133 start-page: e269 year: 2020 end-page: e279 ident: bib0070 article-title: Albuminuria and risk of cardiovascular events and mortality in a general population of patients with type 2 diabetes without cardiovascular disease: a Danish cohort study publication-title: Am. J. Med. – volume: 143 start-page: 337 year: 2021 end-page: 349 ident: bib0135 article-title: Effect of Empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status - results from the EMPEROR-reduced trial publication-title: Circulation – volume: 59 start-page: 2298 year: 2016 end-page: 2307 ident: bib0010 article-title: Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial publication-title: Diabetologia – volume: 70 start-page: 187 year: 2006 end-page: 191 ident: bib0125 article-title: Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark publication-title: Kidney Int. – volume: 15 year: 2020 ident: bib0105 article-title: Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: a Danish nationwide population-based study publication-title: PLoS One – volume: 18 start-page: 169 year: 2016 end-page: 177 ident: bib0040 article-title: Is a reduction in albuminuria associated with renal and cardiovascular protection? A post-hoc analysis of the ALTITUDE trial publication-title: Diabetes Obes. Metab. – volume: 380 start-page: 2295 year: 2019 end-page: 2306 ident: bib0080 article-title: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy publication-title: N. Engl. J. Med. – volume: 14 year: 2019 ident: bib0110 article-title: Primary care physicians’ perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study publication-title: PLoS One – volume: 81 start-page: 1248 year: 2012 end-page: 1253 ident: bib0115 article-title: Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD publication-title: Kidney Int. – volume: 107 start-page: 1 year: 2015 end-page: 8 ident: bib0025 article-title: Microalbuminuria: a parameter that has changed diabetes care publication-title: Diabetes Res. Clin. Pract. – volume: 59 start-page: A4502 year: 2012 ident: bib0055 article-title: Screening for microalbuminuria in patients with type 2 diabetes is incomplete in general practice publication-title: Dan. Med. J. – volume: 358 start-page: 580 year: 2008 end-page: 591 ident: bib0005 article-title: Effect of a multifactorial intervention on mortality in type 2 diabetes publication-title: N. Engl. J. Med. – volume: 8 start-page: 2 year: 2018 end-page: 7 ident: bib0030 article-title: Diagnosis of diabetic kidney disease: state of the art and future perspective publication-title: Kidney Int. Suppl. (2011) – volume: 5 year: 2017 ident: bib0100 article-title: Type 2 diabetes in general practice in Norway 2005-2014: moderate improvements in risk factor control but still major gaps in complication screening publication-title: BMJ Open Diabetes Res. Care – volume: 7 start-page: 128 year: 2019 end-page: 139 ident: bib0035 article-title: Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials publication-title: Lancet Diabetes Endocrinol. – volume: 69 start-page: 2057 year: 2006 end-page: 2063 ident: bib0050 article-title: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective publication-title: Kidney Int. – volume: 6 start-page: 145 year: 2017 end-page: 151 ident: bib0060 article-title: Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care publication-title: Cardiovasc. Endocrinol. – volume: 67 year: 2020 ident: bib0065 article-title: Management of patients with chronic obstructive lung disease, type 2 diabetes and both diseases in primary care in Denmark publication-title: Dan. Med. J. – volume: 43 start-page: 487 year: 2020 end-page: 493 ident: bib0020 article-title: 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD) publication-title: Diabetes Care – volume: 143 start-page: 298 year: 2021 end-page: 309 ident: bib0130 article-title: Efficacy of Dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF publication-title: Circulation – volume: 81 start-page: 1248 year: 2012 ident: 10.1016/j.pcd.2021.07.003_bib0115 article-title: Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD publication-title: Kidney Int. doi: 10.1038/ki.2012.18 – volume: 59 start-page: 2298 year: 2016 ident: 10.1016/j.pcd.2021.07.003_bib0010 article-title: Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial publication-title: Diabetologia doi: 10.1007/s00125-016-4065-6 – volume: 70 start-page: 187 year: 2006 ident: 10.1016/j.pcd.2021.07.003_bib0125 article-title: Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark publication-title: Kidney Int. doi: 10.1038/sj.ki.5001516 – volume: 14 year: 2019 ident: 10.1016/j.pcd.2021.07.003_bib0110 article-title: Primary care physicians’ perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study publication-title: PLoS One doi: 10.1371/journal.pone.0221325 – volume: 91 start-page: 982 year: 2017 ident: 10.1016/j.pcd.2021.07.003_bib0015 article-title: Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits publication-title: Kidney Int. doi: 10.1016/j.kint.2016.11.023 – volume: 7 start-page: 128 year: 2019 ident: 10.1016/j.pcd.2021.07.003_bib0035 article-title: Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials publication-title: Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(18)30314-0 – volume: 6 start-page: 145 year: 2017 ident: 10.1016/j.pcd.2021.07.003_bib0060 article-title: Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care publication-title: Cardiovasc. Endocrinol. doi: 10.1097/XCE.0000000000000135 – volume: 8 start-page: 2 year: 2018 ident: 10.1016/j.pcd.2021.07.003_bib0030 article-title: Diagnosis of diabetic kidney disease: state of the art and future perspective publication-title: Kidney Int. Suppl. (2011) doi: 10.1016/j.kisu.2017.10.003 – volume: 375 start-page: 323 year: 2016 ident: 10.1016/j.pcd.2021.07.003_bib0075 article-title: Empagliflozin and progression of kidney disease in type 2 diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1515920 – volume: 358 start-page: 580 year: 2008 ident: 10.1016/j.pcd.2021.07.003_bib0005 article-title: Effect of a multifactorial intervention on mortality in type 2 diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0706245 – volume: 143 start-page: 337 issue: 4 year: 2021 ident: 10.1016/j.pcd.2021.07.003_bib0135 article-title: Effect of Empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status - results from the EMPEROR-reduced trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.051824 – volume: 15 start-page: 262 issue: 2 year: 2021 ident: 10.1016/j.pcd.2021.07.003_bib0120 article-title: Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015 publication-title: Prim. Care Diabetes doi: 10.1016/j.pcd.2020.09.006 – volume: 383 start-page: 1436 year: 2020 ident: 10.1016/j.pcd.2021.07.003_bib0085 article-title: Dapagliflozin in patients with chronic kidney disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2024816 – volume: 380 start-page: 2295 year: 2019 ident: 10.1016/j.pcd.2021.07.003_bib0080 article-title: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1811744 – volume: 133 start-page: e269 year: 2020 ident: 10.1016/j.pcd.2021.07.003_bib0070 article-title: Albuminuria and risk of cardiovascular events and mortality in a general population of patients with type 2 diabetes without cardiovascular disease: a Danish cohort study publication-title: Am. J. Med. doi: 10.1016/j.amjmed.2019.10.042 – volume: 15 year: 2020 ident: 10.1016/j.pcd.2021.07.003_bib0105 article-title: Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: a Danish nationwide population-based study publication-title: PLoS One doi: 10.1371/journal.pone.0229621 – volume: 43 start-page: 487 year: 2020 ident: 10.1016/j.pcd.2021.07.003_bib0020 article-title: 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD) publication-title: Diabetes Care doi: 10.2337/dci19-0066 – volume: 18 start-page: 169 issue: 2 year: 2016 ident: 10.1016/j.pcd.2021.07.003_bib0040 article-title: Is a reduction in albuminuria associated with renal and cardiovascular protection? A post-hoc analysis of the ALTITUDE trial publication-title: Diabetes Obes. Metab. doi: 10.1111/dom.12600 – volume: 59 start-page: A4502 year: 2012 ident: 10.1016/j.pcd.2021.07.003_bib0055 article-title: Screening for microalbuminuria in patients with type 2 diabetes is incomplete in general practice publication-title: Dan. Med. J. – volume: 143 start-page: 298 issue: 4 year: 2021 ident: 10.1016/j.pcd.2021.07.003_bib0130 article-title: Efficacy of Dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.050391 – volume: 69 start-page: 2057 year: 2006 ident: 10.1016/j.pcd.2021.07.003_bib0050 article-title: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective publication-title: Kidney Int. doi: 10.1038/sj.ki.5000377 – volume: 377 start-page: 839 year: 2017 ident: 10.1016/j.pcd.2021.07.003_bib0090 article-title: Liraglutide and renal outcomes in type 2 diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1616011 – volume: 5 year: 2017 ident: 10.1016/j.pcd.2021.07.003_bib0100 article-title: Type 2 diabetes in general practice in Norway 2005-2014: moderate improvements in risk factor control but still major gaps in complication screening publication-title: BMJ Open Diabetes Res. Care doi: 10.1136/bmjdrc-2017-000459 – volume: 9 start-page: 22 year: 2021 ident: 10.1016/j.pcd.2021.07.003_bib0140 article-title: Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial publication-title: Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(20)30369-7 – volume: 67 year: 2020 ident: 10.1016/j.pcd.2021.07.003_bib0065 article-title: Management of patients with chronic obstructive lung disease, type 2 diabetes and both diseases in primary care in Denmark publication-title: Dan. Med. J. – volume: 107 start-page: 1 year: 2015 ident: 10.1016/j.pcd.2021.07.003_bib0025 article-title: Microalbuminuria: a parameter that has changed diabetes care publication-title: Diabetes Res. Clin. Pract. doi: 10.1016/j.diabres.2014.10.014 – volume: 24 start-page: 302 year: 2013 ident: 10.1016/j.pcd.2021.07.003_bib0045 article-title: Kidney disease and increased mortality risk in type 2 diabetes publication-title: J. Am. Soc. Nephrol. doi: 10.1681/ASN.2012070718 – volume: 23 start-page: 579 year: 2019 ident: 10.1016/j.pcd.2021.07.003_bib0095 article-title: Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies publication-title: Expert Opin. Ther. Targets doi: 10.1080/14728222.2019.1624721 |
| SSID | ssj0061387 |
| Score | 2.2847326 |
| Snippet | •Albuminuria and kidney function are important renal risk factors.•Urine sample collection is a challenge to ensure quality of care.•Trials with SGLT2... To ensure high quality standards in chronic care of type 2 diabetes, it is paramount to ensure regular measurement of clinical risk factors. For prevention of... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1007 |
| SubjectTerms | Albumins Albuminuria Albuminuria - diagnosis Albuminuria - epidemiology Cross-Sectional Studies Denmark - epidemiology Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - epidemiology Diabetic kidney disease Diabetic Nephropathies Glomerular Filtration Rate Humans Primary care Primary Health Care Type 2 diabetes |
| Title | Improving frequency of urinary albumin testing in type 2 diabetes in primary care — An analysis of cross-sectional studies in Denmark |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1751991821001200 https://dx.doi.org/10.1016/j.pcd.2021.07.003 https://www.ncbi.nlm.nih.gov/pubmed/34284949 https://www.proquest.com/docview/2553820361 |
| Volume | 15 |
| WOSCitedRecordID | wos000744235900013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1878-0210 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061387 issn: 1751-9918 databaseCode: AIEXJ dateStart: 20070201 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELa2W4S4IN4sj8pInJCCEsdZ28cFWkEFVaUu1d4ix0mg1ZKt9qUeufEH-GH8Bn4JM47tXVa0PCQuUWTFD2W-zIwn34wJeYolopjOVFSCLYi4FkWk4grueKZ5Gtf9wtbpPn4rDg7kaKQOO51vPhdmORZNI8_P1dl_FTW0gbAxdfYvxB0GhQa4B6HDFcQO1z8S_CpMUE9bnrT9iY5RdWTIWT4ykhuxvEabz7IZhkViuStCYYlhnhDBMYSo16qYWBMbzSybq7GJJ5aUiAO8qppPPg3I-b6H62P6yVaqeTpzyV97UyxwcRJSiBwjwIZukRoc4Hw4WY5dAGl_8hEU1bEt-_BBu0oB1pA0i9I9c4SkgBcSM9eH2hlsF-9gyQZ3JCTirFhPqLdFlkTg6sqfFHu2BuB1LY3MkDWLD1op-aU1aQMbp8_PDNaUZYkt8xqnK9MZCI1HuACcnyU2HTneIttMZEp2yfbgze5o33sH4D3ZQxvDgv2fdss53JjoIl_por2Q9YmGN8h1t5mhgxaEN0mnam6Rq-8cXeM2-RKwSAMW6aSmDovUYZE6LFK8BSxSRj08sMlhkSJu6PfPX-mgoR6FONoGCqlDIXZ1KLxD3u_tDl--jtzJH5HhvD-PykL1GZe67HN0p-qEmUJo2NprqTKjC1NXBVfaVEVWZ5WIdZqwwp4doDionji9S7rNpKnuEyoMevBxIdO-4JXkui4T8AuNEbyUdcp6JPbvODeuLD6ezjLOPf_xNAex5CiWPEayRtojz0IX9woue5h5weU-2RnMcw4Yu6wTD52cJ9x6uL_r9sQjIwcrgb_-dFNNFrOcZeDYIOcg6ZF7LWTC0lMOLqri6sG_rPQhubb6SB-R7ny6qB6TK2Y5P5lNd8iWGMkd9wn8ACzF7yc |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improving+frequency+of+urinary+albumin+testing+in+type+2+diabetes+in+primary+care+%E2%80%94+An+analysis+of+cross-sectional+studies+in+Denmark&rft.jtitle=Primary+care+diabetes&rft.au=Persson%2C+Frederik&rft.au=Charles%2C+Morten&rft.au=Povlsen%2C+Johan+Vestergaard&rft.au=Knudsen%2C+S%C3%B8ren+Tang&rft.date=2021-12-01&rft.pub=Elsevier+Ltd&rft.issn=1751-9918&rft.volume=15&rft.issue=6&rft.spage=1007&rft.epage=1011&rft_id=info:doi/10.1016%2Fj.pcd.2021.07.003&rft.externalDocID=S1751991821001200 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1751-9918&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1751-9918&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1751-9918&client=summon |